Register Login

Perspective Therapeutics Inc (CATX)

(99% Positive) Perspective Therapeutics Inc (CATX) Announces Enrollment Update for treatments Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 8:06 p.m.

    📋 Perspective Therapeutics Inc (CATX) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 08:20:11

    Event Type: Clinical Trial Update

    Event Details:

    Perspective Therapeutics Inc (CATX) Announces Clinical Trial Update Perspective Therapeutics Inc (CATX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: treatments, priorities
    • Collaboration: Perspective Therapeutics Provides Business Updates
      • targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations. For more information, please visit the Company's website at www.perspectivetherapeutics.com. Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995
      • targeting moiety may also be radiolabeled with 203Pb or 68Ga and 64Cu to detect FAP-α expression in individual patients. Preclinical imaging and therapy as well as human imaging results suggest our proprietary targeting ligand has improved levels of target engagement and uptake in tumors, as well as reduced retention in healthy tissues, which may result in a desirable therapeutic index. 2 patients in Cohort 1 had been treated with [212Pb]PSV359 at 2.5 mCi, and 3 patients in Cohort 2 had been treated at 5.0 mCi, for a total of 5 patients as of December 31, 2025
      • targeting melanoma and PSV359 targeting FAP across multiple solid tumors, as well as potential additions to the clinical pipeline to be guided by first-in-human images•Company to present updates at 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026

    🔬 Clinical Development Pipeline (Perspective Therapeutics Inc):

    Product Type Development Stage Therapeutic Area Source
    Nivolumab DRUG Phase PHASE1 Recurrent Melanoma (Skin) ClinicalTrials.gov
    [212Pb]Pb-PSV359 DRUG Phase PHASE1 Pancreatic Ductal Adenocarcinoma ClinicalTrials.gov
    [203Pb]Pb-PSV359 DRUG Phase PHASE1 Pancreatic Ductal Adenocarcinoma ClinicalTrials.gov
    [212Pb]VMT01 DRUG Phase PHASE1 Recurrent Melanoma (Skin) ClinicalTrials.gov
    [203Pb]VMT01 DRUG Phase PHASE1 Recurrent Melanoma (Skin) ClinicalTrials.gov
    [212Pb]VMT-α-NET DRUG Phase PHASE1 Neuroendocrine Tumors Unresectable ClinicalTrials.gov
    [203Pb]VMT-α-NET DRUG Phase PHASE1 Neuroendocrine Tumors Unresectable ClinicalTrials.gov
    [212Pb] VMT-α-NET DRUG Phase EARLY_PHASE1 Neuroendocrine Tumors ClinicalTrials.gov
    [68Ga]VMT02 DRUG Phase PHASE1 Melanoma (Skin) ClinicalTrials.gov
    SPECT/CT DEVICE Phase EARLY_PHASE1 Neuroendocrine Tumor Grade 2 ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Perspective Therapeutics Inc
    • Ticker Symbol: CATX

Search

News categories